TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24714004

Group type: COMPARATOR
Intervention: 25 μg vaginal misoprostol
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 50 μg vaginal misoprostol
Number of subjects: 128
Study: 21971406

Group type: EXPERIMENTAL
Intervention: High saturated fat/high glycemic index (HIGH) diet with high-intensity physical activity (hi-PA)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Low saturated fat/low glycemic index (LOW) diet with high-intensity physical activity (hi-PA)
Number of subjects: 41
Study: 19563429

Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials with stratified, blocked, or paired clusters before randomization (23 trials)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials that adjusted for confounding in analysis (17 trials)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials that did not account for clustering in sample size calculations (10 trials)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials that did not account for the cluster-randomized design in analysis (7 trials)
Number of subjects: 35
Study: 17702878

Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Weight Stable (WS)
Number of subjects: 87
Study: 14770064

Group type: EXPERIMENTAL
Intervention: Intervention to enhance collaborative communication among nurse and physician leaders over 8 months
Number of subjects: 2
Study: 11575229

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg + Hydrochlorothiazide 12.5 mg (V+H)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 8988832

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 1 mg.kg-1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.5 mg.kg-1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 90
Study: 8098251

Group type: EXPERIMENTAL
Intervention: 11.5-F ureteroscopes used in the first 100 patients
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Miniaturised ureteroscope used in the third group of 200 patients
Number of subjects: 400

Group type: COMPARATOR
Intervention: Rigid ureteroscopes used in the second group of 100 patients
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Miniaturised endoscopes used in the second series (1989-1990)
Number of subjects: 400
Study: 2891316

Group type: EXPERIMENTAL
Intervention: Topical levocabastine (ocular)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Topical levocabastine (nasal)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Flunisolide (nasal)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Naphazoline/antazoline (ocular)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Topical levocabastine (nasal and ocular)
Number of subjects: 66
Study: 30236511

Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg orally daily for 24 weeks)
Number of subjects: 31
Study: 26966279

Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) 100 mg/d
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 29
Study: 25543418

Group type: EXPERIMENTAL
Intervention: Acupuncture at 'Siguan' combined with Gallbladder Meridian acupoints
Number of subjects: 87

Group type: COMPARATOR
Intervention: Acupuncture at Gallbladder Meridian acupoints
Number of subjects: 87
Study: 22820064

Group type: EXPERIMENTAL
Intervention: Exercise group (5-min treadmill exercise and 20-min virtual-reality based activity, 3 times a week for 6 weeks)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 92
Study: 19781889

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral self-help program (CBS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Computerized structured writing intervention (SWI)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Waiting list condition (WLC)
Number of subjects: 73
Study: 18508801

Group type: EXPERIMENTAL
Intervention: Eosinophilia and inv(16) present
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Eosinophilia only or inv(16) only
Number of subjects: 400

Group type: COMPARATOR
Intervention: Neither eosinophilia nor inv(16)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both eosinophilia and inv(16)
Number of subjects: 400
Study: 15967762

Group type: EXPERIMENTAL
Intervention: Minimal intervention strategy aimed at assessment and modification of psychosocial prognostic factors
Number of subjects: 314

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 314
Study: 12628627

Group type: EXPERIMENTAL
Intervention: Elated-mood induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Depressed-mood induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: State happiness and positive coping responses
Number of subjects: 0
Study: 12833113

Group type: EXPERIMENTAL
Intervention: 15 mg sibutramine for 14 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10 months open treatment with 15 mg sibutramine and dietary advice
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 36
Study: 9798779

Group type: EXPERIMENTAL
Intervention: Early postoperative intraperitoneal chemotherapy (EPIC) with mitomycin C on postoperative day 1 and 5-fluorouracil on postoperative days 2 to 5
Number of subjects: 248

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 248
Study: 7900522

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No magnesium sulfate (Control group)
Number of subjects: 64
Study: 2612537

Group type: EXPERIMENTAL
Intervention: milnacipran
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 335989

Group type: EXPERIMENTAL
Intervention: Bolus methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dextrose in water (control)
Number of subjects: 0
Study: 31889973

Group type: EXPERIMENTAL
Intervention: Relaxation meditation audio recording during breastfeeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study: 28119434

Group type: EXPERIMENTAL
Intervention: Early group (intravenous edaravone [30 mg] started before or during tPA)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Late group (edaravone started after tPA)
Number of subjects: 165
Study: 25955191

Group type: COMPARATOR
Intervention: 400 IU of vitamin D
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 2500 IU of vitamin D
Number of subjects: 98
Study: 23509106

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoenergetic meals differing in fat and carbohydrate content
Number of subjects: 16
Study: 22321227

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin
Number of subjects: 270

Group type: COMPARATOR
Intervention: High hs-CRP group (hs-CRP ≥ 3 mg/L)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Moderate hs-CRP group (hs-CRP 1-3 mg/L)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Normal hs-CRP group (hs-CRP < 1 mg/L)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: High dose atorvastatin (20 mg)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: High dose atorvastatin (40 mg)
Number of subjects: 270

Group type: COMPARATOR
Intervention: High levels of preprocedural hs-CRP
Number of subjects: 270

Group type: COMPARATOR
Intervention: Diabetes mellitus
Number of subjects: 270

Group type: COMPARATOR
Intervention: Advanced age
Number of subjects: 270

Group type: COMPARATOR
Intervention: Renal failure
Number of subjects: 270
Study: 19382480

Group type: EXPERIMENTAL
Intervention: Tongbian Navel Paste (TBP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Maren Zipi pill (Control)
Number of subjects: 68
Study: 16675486

Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 1739

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 1739
Study: 15569779

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 310
Study: 11412155

Group type: EXPERIMENTAL
Intervention: Nefopam 0.12 mg.kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline 0.9% (Control)
Number of subjects: 40
Study: 9297191

Group type: EXPERIMENTAL
Intervention: Phenazone oxidation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfadimidine acetylation
Number of subjects: 0
Study: 8510001

Group type: EXPERIMENTAL
Intervention: Flumazenil (3.0 mg)
Number of subjects: 4
Study: 3543247

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) recombinant interferon (IFN) alfa‐2b at a dosage of 2 X 10(6) IU/m2 three times weekly.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) recombinant interferon (IFN) alfa‐2b at a dosage of 30 X 10(6) IU/m2 for five consecutive days every 3 weeks.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of patients with prior nephrectomy, no prior treatment, and lack of bone metastases.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both SC and IV routes of administration.
Number of subjects: 97
Study: 31033341

Group type: EXPERIMENTAL
Intervention: RISE program (5-day, 5 hours per day of yoga, meditation, lectures, and experiential activities)
Number of subjects: 121
Study: 27160157

Group type: COMPARATOR
Intervention: Tadalafil 5 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tadalafil de-escalation
Number of subjects: 90
Study: 25403606

Group type: EXPERIMENTAL
Intervention: Tailored stage-matched intervention (SMI)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Nontailored health education intervention (HEI)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 533
Study: 24114306

Group type: EXPERIMENTAL
Intervention: Clinical score group
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Antigen test group
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Delayed antibiotics group
Number of subjects: 1760
Study: 22097104

Group type: EXPERIMENTAL
Intervention: Assertiveness Music Therapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: No Music Assertiveness
Number of subjects: 133

Group type: COMPARATOR
Intervention: Music No Assertiveness
Number of subjects: 133
Study: 19280097

Group type: EXPERIMENTAL
Intervention: Weight Loss plus Aerobic Exercise (WL + AEX)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Weight Loss (WL)
Number of subjects: 86
Study: 17385120

Group type: EXPERIMENTAL
Intervention: Primary eye muscle surgery on 2 horizontal muscles
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Revision surgeries on 2 horizontal muscles
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Primary eye muscle surgeries on 2 vertical recti
Number of subjects: 32
Study: 15473523

Group type: EXPERIMENTAL
Intervention: Iron supplementation (2 mg/kg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 100
Study: 11359489

Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg/ml
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/ml
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% + epinephrine 1:80,000
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 18
Study: 9496328

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of 10,000 IU recombinant human LH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of 10,000 IU recombinant human LH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of 10,000 IU recombinant human LH
Number of subjects: 12
Study: 7993988

Group type: EXPERIMENTAL
Intervention: Enteric-coated tablet (EC)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Plain capsule (PC)
Number of subjects: 113
Study: 2789363

Group type: EXPERIMENTAL
Intervention: Ponsinomycin 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ponsinomycin 800 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ponsinomycin 1200 mg
Number of subjects: 12
Study: 4157126

Group type: EXPERIMENTAL
Intervention: sotalol
Number of subjects: 146

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 146
Study: 29127558

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (4 mg)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (8 mg)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (4 mg)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (8 mg)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Perineural dexamethasone (4 mg) vs Intravenous dexamethasone (4 mg)
Number of subjects: 280

Group type: COMPARATOR
Intervention: 8 mg vs 4 mg dexamethasone
Number of subjects: 280
Study: 28259777

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (25 mg), rilpivirine (25 mg), emtricitabine (200 mg)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (300 mg), rilpivirine (25 mg), emtricitabine (200 mg)
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Number of subjects: 630

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 630
Study: 26497961

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 38

Group type: COMPARATOR
Intervention: No rate control drug (baseline)
Number of subjects: 38
Study: 22038082

Group type: EXPERIMENTAL
Intervention: Good parole officer-parolee relationships
Number of subjects: 374
Study: 20926554

Group type: EXPERIMENTAL
Intervention: Theory-based intervention
Number of subjects: 484

Group type: COMPARATOR
Intervention: Information-only control
Number of subjects: 484
Study: 18506924

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG (LGG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 26
Study: 17323614

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg or Simvastatin 40 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combination of statin + 200 mg micronized fenofibrate
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Statin + 3.6 g n-3 polyene fatty acids (PUFA n-3)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study: 14664413

Group type: EXPERIMENTAL
Intervention: Climex (5 chewable tablets daily between meals)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 10760307

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy plus hematopoietic stem cells
Number of subjects: 553

Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy
Number of subjects: 553
Study: 8622391

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg once daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 1396292

Group type: EXPERIMENTAL
Intervention: Ultrasonographically measured biparietal diameter (BPD) in the second trimester
Number of subjects: 4997

Group type: COMPARATOR
Intervention: Gestational age estimated from last menstrual period (LMP)
Number of subjects: 4997
Study: 3928320

Group type: EXPERIMENTAL
Intervention: 1g temocillin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 2g temocillin
Number of subjects: 26
Study: 31331836

Group type: EXPERIMENTAL
Intervention: Community Health Centre (CHC)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Emergency Department (ED)
Number of subjects: 188
Study: 29720370

Group type: EXPERIMENTAL
Intervention: Low serum 25(OH)D concentrations (<25 nmol/L)
Number of subjects: 854
Study: 27454372

Group type: EXPERIMENTAL
Intervention: Drinker Inventory of Consequences (DrInC) categories
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: DrInC categories
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: DrInC trajectories
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Higher intercepts during treatment
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Steeper negative slopes
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Relationships between trajectories and drinking behavior
Number of subjects: 952
Study: 23786310

Group type: EXPERIMENTAL
Intervention: Preterm formula or mother's own milk (random allocation to raw or pasteurized milk)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intestinal colonization with staphylococci
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intestinal colonization
Number of subjects: 150
Study: 22316732

Group type: EXPERIMENTAL
Intervention: Aesthetic system at 100% accuracy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aesthetic system at 85% accuracy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-aesthetic system at 100% accuracy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-aesthetic system at 85% accuracy
Number of subjects: 0
Study: 20450603

Group type: EXPERIMENTAL
Intervention: Intraoperative (125)I seed implantation (group A)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Surgery alone (group B)
Number of subjects: 298
Study: 17077322

Group type: EXPERIMENTAL
Intervention: First-line polychemotherapy (n = 44)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (n = 4)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Absence of PI9 expression
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low apoptotic index
Number of subjects: 48
Study: 15605857

Group type: EXPERIMENTAL
Intervention: Acoustic-based method for classifying swallowing sounds
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no dysphagia)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Subjects with dysphagia
Number of subjects: 26
Study: 11731725

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with bilateral electrode placement at 50% above the titrated seizure threshold
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 253
Study: 9142008

Group type: EXPERIMENTAL
Intervention: AS-013 (prostaglandin E1 prodrug) administered by intravenous injection 5 d/wk for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 7956270

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT) followed by trabeculectomy, and a second trabeculectomy if needed
Number of subjects: 591

Group type: COMPARATOR
Intervention: Trabeculectomy followed by ALT, and a second trabeculectomy if needed
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Both sequences of surgical treatments
Number of subjects: 591
Study: 3230146

Group type: EXPERIMENTAL
Intervention: A-56234 at 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: A-56234 at 40 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: A-56234 at 60 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: A-56234 at 80 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30005743

Group type: EXPERIMENTAL
Intervention: Atorvastatin (lipophilic)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rosuvastatin (hydrophilic)
Number of subjects: 10
Study: 26759468

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 0
Study: 25788517

Group type: EXPERIMENTAL
Intervention: Video counseling
Number of subjects: 40

Group type: COMPARATOR
Intervention: Face-to-face counseling
Number of subjects: 40
Study: 23594858

Group type: EXPERIMENTAL
Intervention: Ciclosporin (CSA)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Tacrolimus (TAC)
Number of subjects: 148
Study: 20873905

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Progressive Relaxation Training (PRT)
Number of subjects: 79
Study: 18297975

Group type: EXPERIMENTAL
Intervention: Psychotherapy trials
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy trials
Number of subjects: 237

Group type: COMPARATOR
Intervention: Comparison of psychotherapy and pharmacotherapy trials
Number of subjects: 237
Study: 16802855

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.2 mg/kg buccally
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.2 mg/kg sublingually
Number of subjects: 30
Study: 14711140

Group type: EXPERIMENTAL
Intervention: Intramuscular alefacept 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous alefacept
Number of subjects: 0
Study: 10836009

Group type: EXPERIMENTAL
Intervention: Curative treatment for hepatic malignancies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigational therapies for hepatic malignancies
Number of subjects: 0
Study: 9190980

Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: COMPARATOR
Intervention: Beta-carotene and Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Non-high-risk HPV types
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Age <25 years
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Douching after sexual intercourse
Number of subjects: 69
Study: 1565349

Group type: EXPERIMENTAL
Intervention: Ibuprofen, 600 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6323378

Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Oral mecillinam
Number of subjects: 64

Group type: COMPARATOR
Intervention: Supportive care only (Control)
Number of subjects: 64
Study: 31373188

Group type: EXPERIMENTAL
Intervention: Smartphone heart rate monitoring application
Number of subjects: 24
Study: 29525763

Group type: EXPERIMENTAL
Intervention: Pilates once a week (PG1)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Pilates twice a week (PG2)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Pilates three times a week (PG3)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Booklet group (BG)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Pilates twice a week (PG2) vs Pilates once a week (PG1)
Number of subjects: 296